共 50 条
High intensity focused ultrasound treatment for diffuse uterine leiomyomatosis: a feasibility study
被引:6
作者:
Zhang, Xiaofei
[1
]
Tian, Tian
[2
]
Zhu, Jialiang
[3
]
Lin, Bin
[1
]
Feng, Xiao
[1
]
Zhang, Lian
[4
,5
]
Yang, Xinhua
[1
]
Aili, Aixingzi
[1
]
机构:
[1] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Gynecol, 2699 West Gaoke Rd, Shanghai 201204, Peoples R China
[2] Shanghai Xinhua Harvard Med Ctr, Dept Gynecol, Shanghai, Peoples R China
[3] Tongji Univ, Scholl Med, Shanghai Matern & Infant Hosp 1, Dept MRI, Shanghai, Peoples R China
[4] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Engn Med Cofounded Chong, Chongqing, Peoples R China
[5] Chongqing Med Univ, Coll Biomed Engn, Minist Sci & Technol, Chongqing Key Lab Ultrasoundin Med & Engn, Chongqing, Peoples R China
关键词:
Diffuse uterine leiomyomatosis;
high-intensity focused ultrasound;
conservative therapy;
MRI;
feasibility study;
ARTERY EMBOLIZATION;
UTERUS;
HIFU;
FIBROIDS;
WOMEN;
D O I:
10.1080/02656736.2020.1815871
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Objective To investigate the safety and efficacy of high-intensity focused ultrasound (HIFU) treatment for diffuse uterine leiomyomatosis (DUL). Methods Eight patients with DUL were admitted to the Department of Gynecology of Shanghai First Maternity and Infant Hospital and underwent HIFU treatment. MRI was performed before and one day after HIFU treatment for the evaluation of lesion ablation. The uterine size was measured at 3-8 months after HIFU ablation. The menstrual volume score and serum levels of hemoglobin and CA-125 were measured pre-HIFU ablation and 12-36 months post-HIFU ablation. Results After an average of 5.9 months of follow-up after HIFU treatment, an average uterine volume reduction of 67.6% was observed. Menstruation returned to normal in all patients, and their serum HGB and CA-125 levels also returned to normal after an average of 19.1 months of clinical follow-up. The quality of life of all patients improved significantly. Conclusion HIFU treatment is safe and effective in the treatment of patients with DUL.
引用
收藏
页码:1060 / 1065
页数:6
相关论文